Effects of AKT Inhibitors for PIK3CA/AKT1/PTEN-Altered Advanced or Metastatic Breast Cancer: A Meta-Analysis of Randomized Clinical Trials

被引：0

作者：

de Moraes, Francisco Cezar Aquino ^{[1
]}

Sano, Vitor Kendi Tsuchiya ^{[2
]}

Pereira, Caroline R. M. ^{[3
]}

de Laia, Estella Aparecida ^{[4
]}

Stecca, Carlos ^{[5
]}

Magalhaes, Maria Cristina Figueroa ^{[5
]}

Tarantino, Paolo ^{[6
]}

机构：

[1] Fed Univ, Dept Med, Belem, Para, Brazil

[2] Univ Fed Acre, Dept Med, Rio Branco, Acre, Brazil

[3] Univ Porto, Fac Med Porto, Porto, Portugal

[4] Fluminense Fed Univ, Dept Med, Niteroi, RJ, Brazil

[5] Mackenzie Evangel Univ Hosp, Dept Med Oncol, Curitiba, Parana, Brazil

[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

来源：

CLINICAL BREAST CANCER | 2025年 / 25卷 / 05期

关键词：

Advanced breast cancer; AKT Inhibitors; PIK3CA/AKT1/PTEN-Altered; Meta-analysis; Randomized Clinical Trials; PROGRESSION-FREE SURVIVAL; DOUBLE-BLIND; MUTATIONS; PATHWAY; PLACEBO; CAPIVASERTIB; FULVESTRANT;

D O I：

10.1016/j.clbc.2025.03.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose We aimed to answer the following question: How effective is the addition of AKT inhibitors to the treatment of advanced or metastatic breast cancer? Methods We searched PubMed, Embase and Cochrane for randomized controlled trials (RCTs) that investigated AKT inhibitors for advanced or metastatic BC. We computed hazard-ratios (HRs) for binary endpoints. Results A total of 5 RCTs were included in the meta-analysis, comprising 1,334 patients with BC. The use of AKT inhibitors demonstrated a significant improvement in OS (HR 0.70; 95% CI, 0.58-0.85; P < .001) and PFS (HR 0.6797; 95% CI, 0.5499-0.8403; P < .001) in the overall population. Within the PIK3CA/AKT1/PTEN-altered subgroup (n = 645), the OS rate also significantly favored AKT inhibitors over the control group (HR 0.62; 95% CI, 0.42-0.92; P = .019), as well as PFS (HR 0.5224; 95% CI, 0.3366-0.8105; P = .004). Conclusions Our findings suggest that the incorporation of AKT inhibitors holds promise for treating patients with advanced or metastatic PIK3CA/AKT1/PTEN-altered BC.

引用

页码：391 / 400.e15

页数：25

共 51 条

[1] Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha [J].

Alessi, DR ;

James, SR ;

Downes, CP ;

Holmes, AB ;

Gaffney, PRJ ;

Reese, CB ;

Cohen, P .

CURRENT BIOLOGY, 1997, 7 (04) :261-269

[2] Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer [J].

Araki, Kazuhiro ;

Miyoshi, Yasuo .

BREAST CANCER, 2018, 25 (04) :392-401

[3] Current and future burden of breast cancer: Global statistics for 2020 and 2040 [J].

Arnold, Melina ;

Morgan, Eileen ;

Rumgay, Harriet ;

Mafra, Allini ;

Singh, Deependra ;

Laversanne, Mathieu ;

Vignat, Jerome ;

Gralow, Julie R. ;

Cardoso, Fatima ;

Siesling, Sabine ;

Soerjomataram, Isabelle .

BREAST, 2022, 66 :15-23

[4] An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer [J].

Asnaghi, Riccardo ;

Antonarelli, Gabriele ;

Battaiotto, Elena ;

Castellano, Grazia ;

Guidi, Lorenzo ;

Izzo, Davide ;

Zagami, Paola ;

Trapani, Dario ;

Curigliano, Giuseppe .

EXPERT OPINION ON PHARMACOTHERAPY, 2025, 26 (03) :235-247

[5] Sequence analysis of mutations and translocations across breast cancer subtypes [J].

Banerji, Shantanu ;

Cibulskis, Kristian ;

Rangel-Escareno, Claudia ;

Brown, Kristin K. ;

Carter, Scott L. ;

Frederick, Abbie M. ;

Lawrence, Michael S. ;

Sivachenko, Andrey Y. ;

Sougnez, Carrie ;

Zou, Lihua ;

Cortes, Maria L. ;

Fernandez-Lopez, Juan C. ;

Peng, Shouyong ;

Ardlie, Kristin G. ;

Auclair, Daniel ;

Bautista-Pina, Veronica ;

Duke, Fujiko ;

Francis, Joshua ;

Jung, Joonil ;

Maffuz-Aziz, Antonio ;

Onofrio, Robert C. ;

Parkin, Melissa ;

Pho, Nam H. ;

Quintanar-Jurado, Valeria ;

Ramos, Alex H. ;

Rebollar-Vega, Rosa ;

Rodriguez-Cuevas, Sergio ;

Romero-Cordoba, Sandra L. ;

Schumacher, Steven E. ;

Stransky, Nicolas ;

Thompson, Kristin M. ;

Uribe-Figueroa, Laura ;

Baselga, Jose ;

Beroukhim, Rameen ;

Polyak, Kornelia ;

Sgroi, Dennis C. ;

Richardson, Andrea L. ;

Jimenez-Sanchez, Gerardo ;

Lander, Eric S. ;

Gabriel, Stacey B. ;

Garraway, Levi A. ;

Golub, Todd R. ;

Melendez-Zajgla, Jorge ;

Toker, Alex ;

Getz, Gad ;

Hidalgo-Miranda, Alfredo ;

Meyerson, Matthew .

NATURE, 2012, 486 (7403) :405-409

[6] Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Baselga, Jose ;

Im, Seock-Ah ;

Iwata, Hiroji ;

Cortes, Javier ;

De laurentiis, Michele ;

Jiang, Zefei ;

Arteaga, Carlos L. ;

Jonat, Walter ;

Clemons, Mark ;

Ito, Yoshinori ;

Awada, Ahmad ;

Chia, Stephen ;

Jagiello-Gruszfeld, Agnieszka ;

Pistilli, Barbara ;

Tseng, Ling-Ming ;

Hurvitz, Sara ;

Masuda, Norikazu ;

Takahashi, Masato ;

Vuylsteke, Peter ;

Hachemi, Soulef ;

Dharan, Bharani ;

Di Tomaso, Emmanuelle ;

Urban, Patrick ;

Massacesi, Cristian ;

Campone, Mario .

LANCET ONCOLOGY, 2017, 18 (07) :904-916

[7] Akt inhibitors: mechanism of action and implications for anticancer therapeutics [J].

Bhutani, Jaikrit ;

Sheikh, Asfandyar ;

Niazi, Asfandyar Khan .

INFECTIOUS AGENTS AND CANCER, 2013, 8

[8] The nuts and bolts of PROSPERO: An international prospective register of systematic reviews [J].

Alison Booth ;

Mike Clarke ;

Gordon Dooley ;

Davina Ghersi ;

David Moher ;

Mark Petticrew ;

Lesley Stewart .

Systematic Reviews, 1 (1)

[9] Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges [J].

Cerma, Krisida ;

Piacentini, Federico ;

Moscetti, Luca ;

Barbolini, Monica ;

Canino, Fabio ;

Tornincasa, Antonio ;

Caggia, Federica ;

Cerri, Sara ;

Molinaro, Alessia ;

Dominici, Massimo ;

Omarini, Claudia .

BIOMEDICINES, 2023, 11 (01)

[10] PTEN and the PI3-Kinase Pathway in Cancer [J].

Chalhoub, Nader ;

Baker, Suzanne J. .

ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2009, 4 :127-150

← 1 2 3 4 5 6 →